🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseHas anyone dealt with glp-1 hepatoprotection?

Has anyone dealt with glp-1 hepatoprotection?

GenomicsKate Fri, Jul 11, 2025 at 12:32 PM 33 replies 1,678 viewsPage 1 of 7
This thread is more than 11 months old. Information may be outdated. Consider searching for more recent discussions.
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Jul 11, 2025 at 1:57 PM#1

Hi all, brand new here. My endo just prescribed semaglutide and I have a question about has anyone dealt with glp-1 hepatoprotection?.

Sorry if this has been asked before — I did try searching but the amount of information here is overwhelming (in a good way). I am on week 1 and everything is new to me.

Any guidance appreciated. You all seem really knowledgeable and I am glad I found this community.

6 18DebRD_ATL, KristenIndy, MarkLI_maint and 3 others
Reply Quote Save Share Report
Dr.CardioMD
VIP Member
2,678
14,567
Dec 2023
Cleveland, OH
Jul 11, 2025 at 2:14 PM#2
GenomicsKate said:
Has anyone dealt with glp-1 hepatoprotection?

I respect GenomicsKate perspective but I think this oversimplifies things a bit. Re: Has anyone dealt with glp-1 — the effect size varies considerably by population.

I am not saying GenomicsKate wrong entirely — just that the picture is more nuanced than a blanket statement. The SURMOUNT data specifically shows baseline BMI-dependent responses.

Last edited: Jul 11, 2025 at 8:14 PM
40 9Dr.NephBHM_UK, kim_atl_prep, sarah_TO and 37 others
Reply Quote Save Share Report
oliver_london
Member
312
1,345
Aug 2024
London, UK
Jul 11, 2025 at 2:31 PM#3

+1 to GenomicsKate. Especially the point about "Has anyone dealt with glp-1 hepatoprotec..." — I have seen the same in my own experience with Has anyone dealt with.

10 14Dr.LeslieOBGYN, MikeNYC_runner and 7 others
Reply Quote Save Share Report
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Jul 11, 2025 at 2:48 PM#4

As a healthcare provider, I want to add some clinical context to this discussion on Has anyone dealt with glp-1.

Building on what GenomicsKate said — the evidence base here is well-established. The key publications to reference are from the FLOW program[1].

Key clinical points:

  1. Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
  2. Side effect profile is predictable and usually manageable with standard protocols
  3. Monitoring should include baseline labs and follow-up at 3-month intervals
  4. Patient education significantly improves outcomes and adherence

Standard disclaimer: this is educational, not individualized medical advice.

References:
[1] See thread title for relevant study identification.
26 13JenMemphis, pat_auckland, Dr.GastroMayo and 23 others
Reply Quote Save Share Report
Dr.NateNeph
VIP Member
2,987
16,234
Dec 2023
Houston, TX
Jul 11, 2025 at 3:05 PM#5
oliver_london said:
Especially the point about "Has anyone dealt with glp-1 hepatoprotec

Gonna push back on this one. Has anyone dealt with glp-1 is not that straightforward in my experience. I have been on this for 18 months and the reality is messier than the trials suggest.

Don't get me wrong — the medication works. But adherence is harder than people admit. We should be honest about that.

Last edited: Jul 11, 2025 at 5:05 PM
4 9RickReta_CO, PharmHunterJen, TomTeleRx and 1 other
Reply Quote Save Share Report
1237

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register